PharmaShots | Incisive News in 3 Shots

Subscribe Now

eccogene

Eccogene Reports the First Patient Dosing with ECC5004/AZD5004 in P-IIb Trial of Obesity and T2D, Triggering $60M Milestone from AstraZeneca

Eccogene Reports the First Patient Dosing with ECC5004/AZD5004 in P-IIb Trial of Obesity and T2D, Triggering $60M Milestone from A...

October 23, 2024

Eccogene Enters into a Collaboration Agreement with AstraZeneca to Develop and Commercialize ECC5004 for Cardiometabolic Diseases

Eccogene Enters into a Collaboration Agreement with AstraZeneca to Develop and Commercialize ECC5004 for Cardiometabolic Diseases

November 9, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us